Eli Lilly
Trade Eli Lilly 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies.
LLY Key Statistics
Stock Snapshot
Eli Lilly(LLY) stock is priced at $1,146.00, giving the company a market capitalization of 1.08T. It carries a P/E multiple of 39.40 and pays a dividend yield of 0.58%.
On 2026-09-04, Eli Lilly(LLY) stock traded between a low of $1,138.31 and a high of $1,159.00. Shares are currently priced at $1,146.00, which is +0.7% above the low and -1.1% below the high.
The Eli Lilly(LLY)'s current trading volume is 2.22M, compared to an average daily volume of 2.51M.
During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.
During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.
LLY News
Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) is launching a new Phase 1 study on tirzepatide in...
Amgen’s AMGN key pipeline candidate MariTide is a closely watched drug in the obesity market. The drug can give Amgen exposure to one of the industry's fastest-...
These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Dell Hits New Highs 9/04/2026 Among the best stocks in earnings performance, highly rated...
Analyst ratings
81%
of 32 ratingsMore LLY News
Eli Lilly (LLY -0.17%) has achieved impressive returns in recent years, driven by soaring demand for tirzepatide, a medicine sold as Mounjaro for diabetes and Z...
Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Phase 1 Inflammation Study in Focus as Eli Lilly Advances New Oral Drug The s...
J.P. Morgan analyst Chris Schott maintained a Buy rating on Eli Lilly & Co today and set a price target of $1,400.00. Chris Schott has given his Buy rating due...
Eli Lilly stock has delivered very strong gains over the past five years, yet current valuation checks still point to a meaningful gap between the share price a...
Key Points The results of a study Eli Lilly ran suggest that patients older than 55 on Zepbound incur lower healthcare costs than those not on Zepbound. This...
Eli Lilly LLY announced that it has entered into a definitive agreement to acquire clinical-stage biotech Merida Biosciences in an all-cash transaction for up t...
Investing Insurers Are Pulling Back From GLP-1 Drugs. The FDA Just Handed Eli Lilly Its Best Weapon Yet Employer coverage of GLP-1 drugs is collapsing heading i...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.